- Home
- TOVX vs SNPX Comparison
TOVX vs SNPX Comparison
Compare TOVX & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- SNPX
- Stock Information
- Founded
- TOVX 2001
- SNPX 2012
- Country
- TOVX United States
- SNPX United States
- Employees
- TOVX N/A
- SNPX N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- TOVX Health Care
- SNPX Health Care
- Exchange
- TOVX Nasdaq
- SNPX Nasdaq
- Market Cap
- TOVX 3.6M
- SNPX 3.1M
- IPO Year
- TOVX 2006
- SNPX N/A
- Fundamental
- Price
- TOVX $0.64
- SNPX $2.40
- Analyst Decision
- TOVX Hold
- SNPX Strong Buy
- Analyst Count
- TOVX 1
- SNPX 1
- Target Price
- TOVX N/A
- SNPX $14.00
- AVG Volume (30 Days)
- TOVX 2.4M
- SNPX 5.6K
- Earning Date
- TOVX 05-20-2025
- SNPX 05-19-2025
- Dividend Yield
- TOVX N/A
- SNPX N/A
- EPS Growth
- TOVX N/A
- SNPX N/A
- EPS
- TOVX N/A
- SNPX N/A
- Revenue
- TOVX N/A
- SNPX N/A
- Revenue This Year
- TOVX N/A
- SNPX N/A
- Revenue Next Year
- TOVX N/A
- SNPX N/A
- P/E Ratio
- TOVX N/A
- SNPX N/A
- Revenue Growth
- TOVX N/A
- SNPX N/A
- 52 Week Low
- TOVX $0.74
- SNPX $1.84
- 52 Week High
- TOVX $12.25
- SNPX $5.09
- Technical
- Relative Strength Index (RSI)
- TOVX 23.36
- SNPX 51.45
- Support Level
- TOVX $1.32
- SNPX $2.34
- Resistance Level
- TOVX $1.45
- SNPX $2.58
- Average True Range (ATR)
- TOVX 0.14
- SNPX 0.11
- MACD
- TOVX -0.07
- SNPX 0.03
- Stochastic Oscillator
- TOVX 2.92
- SNPX 65.91
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.